ビタミンD受容体のラキッツ関連変異体に対する選択性アゴニストの構造ベースの設計
Steve L Swann1, Joel Bergh, Mary C Farach-Carson
1Department of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, USA.
Journal of the American Chemical Society
|November 15, 2002
まとめ
新しい非ステロイドビタミンD受容体 (VDR) アナログは,ヒトのビタミンD耐性ラキット (hVDRR) を引き起こすVDR変異を効果的に治療します. これらの化合物は,核VDRに対する高い効能と選択性を示し,有望な治療戦略を提供している.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 分子生物学は分子生物学である.
- 構造生物学 構造生物学とは
背景:
- ビタミンD受容体 (VDR) を含む核およびステロイドホルモン受容体は,発育およびホメオスタシスのための遺伝子転写を調節する.
- VDRの変異は,高血清1,25 (OH) 2 (D) 3と重度の骨欠陥によって特徴づけられるヒトのビタミンD耐性ラキス (hVDRR) と関連しています.
- hVDRRに関連したVDR変異は,しばしばリガンド結合とトランザクティベーションを損なう,特にArg274 --> Leu変異は,ホルモン反応を1000倍以上減らす.
研究 の 目的:
- Arg274 --> Leu hVDRRに関連した変異体を標的とした新しい非ステロイドVDRアナログの設計と合成.
- 欠陥VDR機能を補完するこれらのアナログの有効性と効力を評価する.
- 核VDRのための設計されたアナログの,膜関連VDR経路に対する選択性を評価する.
主な方法:
- VDRアゴニストのLG190155.5をベースにした非ステロイド類のアナログの集中ライブラリを作成するために,コンピュータ支援分子設計が採用されました.
- アナログは,VDRにおけるArg274 --> Leu変異によって引き起こされる構造的,機能的欠陥を補完するために特別に設計されました.
- 設計されたアナログと対照化合物の活動は,hVDRRに関連した変異体VDR.の文脈で評価されました.
主要な成果:
- 設計された非ステロイド類似薬の半分は,Arg274 --> Leu hVDRR変異体に対して実質的な活性を示した.
- 構造的に類似した対照化合物は有意な活性を示せず,設計された類似体の特異性を強調しました.
- 7つの最も強力なアナログは,変異受容体における1,25(OH)(2)D(3) よりも16〜526倍有効で,EC(50) 値は3.3-121 nMの範囲でした.
- これらのアナログは,細胞のカルシウム流入を刺激することなく,核のVDRを選択的に活性化させ,膜関連VDRの活性化がないことを示した.
結論:
- 新しい非ステロイドVDR類は,hVDRRに関連したVDR変異体を効果的に標的にし,活性化することができます.
- 設計されたアナログは,特定の変異の文脈で,天然のホルモン1,25 (OH) 2 (D) 3と比較して,著しく高い効能と選択性を示す.
- これらの発見は,欠陥のあるリガンド結合機能を回避する選択的なVDR調節器を開発することによって,hVDRRのための有望な治療法を示しています.
さらに関連する動画
10:01Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
関連する概念動画
01:25Drug-Receptor Bonds
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...